ARCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Arcturus Therapeutics Holdings Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.42+0.08 (+0.77%)
Close on Oct 19, 2026
- Market cap
- $296.17M
- P/E (TTM)
- –
- Dividend yield
- –
Arcturus Therapeutics Holdings Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -348.3%
- Net margin
- -317.6%
- Return on equity, FY2025
- -28.9%
Financial strength
- Current ratio
- 5.88
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 571.0%
Valuation
- P/E ratio
- –
- Price to sales
- 10.09
- Price to book
- 1.72
- Dividend yield
- –